Global Cat Allergy in Human Market - 2024-2032

The global cat allergy in human market reached US$ 0.73 billion in 2023 and is expected to reach US$ 1.19 billion by 2032, growing at a CAGR of 5.6% during the forecast period 2024-2032.

Cat allergy can cause various symptoms in humans such as sneezing, runny nose, cough, hives, red and itchy eyes, rashes on skin, etc. In some very sensitive populations with asthma, exposure to cat allergens may cause severe asthma flare-ups. These cat allergens include proteins in saliva, urine, dander, etc. There are eight known proteins/allergens that cause allergies in human, classified from (Fel d 1 to Fel d 8), and the most common culprit is Fel d 1- causing the majority of cases.

The most common treatment options for cat allergy in humans include antihistamines, steroidal nasal sprays, decongestant nasal sprays, leukotriene antagonists, etc. No immunotherapy drugs have been approved till now specifically for cat allergy, hence the treatment algorithm includes managing the symptoms.

The market for cat allergy in human is aniticipated to be driven by the rising pet adoption rates, rising R&D, and novel drug development activities.

Market Dynamics: Drivers & Restraints

The rising adoption of cats is driving cat allergy in human market

Globally, the ownership of pets is rising, among them, dogs and cats are the popular ones. This rising adoption is fostered by increasing awareness of mental benefits caused by pet companionship, increasing awareness of animal welfare, rising urbanization, and increasing disposable income to cater to the needs of pets, etc. Similar to the rising pet adoption rate, the number of population who are allergic to pets is also rising globally. For instance, according to the Asthma and Allergy Foundation of America, nearly 10 to 20% of the global population is allergic to pets, especially cats and dogs, and this allergic population is rising globally.

Moreover, asthmatic patients are at a higher risk of cat allergies and related incidence of anaphylaxis (a serious life-threatening allergic reaction). As the global prevalence of asthma is rising, these populations are at a higher risk of cat allergy. For instance, a study published in the Chinese Medical Journal Pulmonary and Critical Care Medicine in September 2024, stated that the incidence of new asthma cases in 2030 is expected to reach 11.90 million from 6.44 million in 2020. A similar trend is observed in all the countries across the world. In the U.S. nearly 6.94 million new asthma cases are expected to be reported in 2030, from 5.37 million cases in 2020.

Concerning the pet adoption rate, as per the American Veterinary Medical Association, the cat population in the U.S. is expected to drastically rise from 65 million in 2020 to more than 82 million in 2030.

This increasing trend coupled with a rising population who are allergic to cats can significantly increase the demand for advanced therapies and propel the overall market growth in the forecast period.

Underreporting of cat allergy can significantly hinder cat allergy in human market growth.

Many individuals develop cat allergy after prolonged exposure to cat allergens, and most of the time, the symptoms are misdiagnosed as allergic rhinitis. Many individuals may not consult or report their symptoms to the doctor, which may lead to underreporting of cases and consecutively lead to lower treatment rates. This can be a significant barrier in underdeveloped countries, leading to a lower treatment rate. This underreporting can also hinder the development of novel drugs such as immunotherapies because the manufacturers may not see the area to be potential for exploration. All of these factors can hinder the market growth in the forecasted period.

Segment Analysis

The global cat allergy in human market is segmented based on treatment type, route of administration, mode of prescription, distribution channel, and region.

Antihistamines in the treatment type segment have the highest market share.

Antihistamines are the drugs designated for the treatment of allergy symptoms and are prescribed for the treatment of various allergic conditions including pet allergy. Antihistamines work by inhibiting the histaminic receptors that are involved in the allergy-induced inflammatory response pathway. Antihistamines that are aimed at treating allergies act specifically on H-1 receptors, and nearly 45 H1 receptor antagonists have been discovered till now. The research efforts to discover novel next-generation antihistamines are still ongoing and manufacturers are investing heavily to bring them into the market and tackle the growing need of the allergic population.

For cat allergy, the commonly used antihistamines are fexofenadine, loratadine, desloratadine, cetirizine, levocetirizine, etc. All these drugs antagonize the H1 receptors and prevent the binding of histamine, a major transmitter released in response to cat allergen. Drugs acting through this mechanism act quickly and address the bothering symptoms of cat allergy. Moreover, these drugs are available over the counter and have minimal side effects, making them the preferred choice of drugs by both physicians and patients.

Geographical Analysis

North America is expected to hold a significant share of the cat allergy in human market.

North America is estimated to hold the highest market share throughout the forecast period, owing to factors like increasing pet ownership, rising population who are allergic to cats, heightened awareness of cat allergies, and strong presence of market players who are offering advanced therapies.

Moreover, the population in the region is highly aware of their allergic symptoms and consults physicians regularly. This results in a higher treatment rate for cat allergy in the region. Moreover, the drugs that are commonly prescribed for cat allergy are widely available in the U.S. both in branded and generic versions. For instance, popular brands such as "Zyrtec" by Kenvue Brands LLC., "Allegra" by Sanofi, and "Benadryl" by Johnson & Johnson Services, Inc. are the most popular drugs for cat allergy in the region. These drugs are available in the U.S. through various distribution channels providing easy access to patients.

Hence all these factors including the revenue generated by the market players contribute to the region's dominance in the global cat allergy in human market.

Competitive Landscape

The major global players in the cat allergy in human market are Kenvue Brands LLC., Bayer AG, Sanofi, Haleon Group of Companies., GSK Plc., Johnson & Johnson Services, Inc., Teva Pharmaceuticals USA, Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., and Perrigo Company. among others.

Emerging Players

The emerging players in the cat allergy in human market include ANGANY Inc. among others.

Key Developments

• In January 2024, ANGANY Inc., announced the positive results of phase 1 clinical trials for its novel biological drug ANG-101. Angany is the first company to initiate clinical trials for cat allergy in humans. The investigational candidate which is an immunotherapy drug showed a significant safety profile, with mild and reversible side effects among the subject population.
• In August 2024, the U.S. Food and Drug Administration (FDA) approved neffy (epinephrine nasal spray) for the treatment of type 1 allergic reactions including life-threatening anaphylaxis. Neffy demonstrated a significant improvement in blood pressure, and heart rate, similar to epinephrine injection. Although anaphylaxis is rare in cat allergy patients, this can be a life-saving treatment in the particular population group who experience it.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and Treatment Type pipelines, and forecasts upcoming pharmaceutical advancements.
• Treatment Type Performance & Market Positioning: Analyzes Treatment Type performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into drug-enzyme-type development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Treatment Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Cat allergy in human market report would provide approximately 70 tables, 64 figures, and 170 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.